52 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
for any product candidates we may develop; the pricing and reimbursement of our product candidates, if approved, including the possibility for reduced … , are likely to be their efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement. Manufacturing We do not own
8-K
EX-10.1
cksa4mm11
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
dcz mceg3o7rnz
28 Apr 23
Annual report to shareholders
7:03am
8-K
EX-99.1
kbvvbhn w445qxswvw0
4 Aug 22
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:15am
8-K
EX-10.1
2zi2dyb9u mgz
30 Nov 21
Entry into a Material Definitive Agreement
4:18pm
S-3ASR
EX-4.5
8n1mhso j9
10 Nov 21
Automatic shelf registration
5:19pm
S-3ASR
EX-1.2
hkyj1b4v
10 Nov 21
Automatic shelf registration
5:19pm
S-3ASR
EX-4.4
6xmp6
10 Nov 21
Automatic shelf registration
5:19pm
S-3ASR
d703 0ft3
10 Nov 21
Automatic shelf registration
5:19pm